


Pharma in the "Post-Pandemic" phase.

Our data from 2020 showed us that Pharma was hot; and in our 2021 Pharma Report, we saw that Pharma's reputation continued to climb during the first half of 2021.




But in June '21, we saw the beginning of the end for Pharma's reputation high coming "out of" the pandemic.



Pharma Burnout

The global medical demands that boosted Pharma's reputation at the beginning of the pandemic has fizzled out in the first half of 2022—their Scores are down across the board.



Reputation Scores by Industry Q1 & Q2 2022 U.S.

Industry	Score	Change	Companies
Health Care Equipment & Services		N/A	
Semiconductors & Semiconductor Equipment		N/A	10
Automobiles & Components			
Pharmaceuticals, Biotechnology & Life Sciences	67.6	▼ 2.9	8
Consumer Durables & Apparel		▼ 2.2	
Media & Entertainment		▼ 1.7	
Diversified Financials		▼ 1.5	
Technology Hardware & Equipment		▼ 1.5	
Food, Beverage & Tobacco		▼ 1.4	
Software & Services		▼ 1.3	
Banks		▼ 1.2	
Transportation		▼ 1.2	
Capital Goods		▼ 1.1	
Insurance		▼ 0.8	
Telecommunication Services		▼ 0.8	
Retailing		▼ 0.7	
Household & Personal Products		▼ 0.6	
Consumer Services		▽ 0.4	
TOTAL		▼ 0.9	146

Pharmaceuticals, Biotechnology & Life Sciences has an Average 67.6 with a significant decrease of 2.9 points, the largest YoY decrease out of any industry.

When we look at Pharma's 2022 Driver Factors, we see that the industry's weakest pain points have to do with **how the industry is operating**, rather than the products themselves.

